pCMV-PEmax-P2A-BSD Citations (3)
Originally described in: Enhanced prime editing systems by manipulating cellular determinants of editing outcomes.Chen PJ, Hussmann JA, Yan J, Knipping F, Ravisankar P, Chen PF, Chen C, Nelson JW, Newby GA, Sahin M, Osborn MJ, Weissman JS, Adamson B, Liu DR Cell. 2021 Oct 28;184(22):5635-5652.e29. doi: 10.1016/j.cell.2021.09.018. PubMed Journal
Articles Citing pCMV-PEmax-P2A-BSD
| Articles |
|---|
Predicting prime editing efficiency and product purity by deep learning.
Mathis N, Allam A, Kissling L, Marquart KF, Schmidheini L, Solari C, Balazs Z, Krauthammer M, Schwank G.
Nat Biotechnol. 2023 Jan 16. doi: 10.1038/s41587-022-01613-7.
PubMed
Associated Plasmids |
| U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations. Walter DM, Cho K, Sivakumar S, Denney D, Lee IT, Dohlman AB, Heinz JM, Shurberg E, Jiang KX, Gupta AA, Frampton GM, Meyerson M. bioRxiv [Preprint]. 2025 Sep 18:2025.03.21.644128. doi: 10.1101/2025.03.21.644128. PubMed |
| Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. Zhu J, Xiong Y, Zhang Y, Liang H, Cheng K, Lu Y, Cai G, Wu Y, Fan Y, Chen X, Zhu H, Ding Z, Zhang W. Cancer Commun (Lond). 2025 Aug;45(8):1038-1071. doi: 10.1002/cac2.70036. Epub 2025 May 29. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.